Exploring Drug Hypersensitivity Syndrome: A Dermatologic Perspective

Drug hypersensitivity syndrome (DHS) can present significant dermatologic challenges. This article delves into its mechanisms, diagnosis, and management.

Drug hypersensitivity syndrome (DHS), also known as drug reaction with eosinophilia and systemic symptoms (DRESS), is a severe drug-induced reaction that presents with a complex array of clinical symptoms, particularly affecting the skin. Understanding the mechanisms, clinical presentation, and management from a dermatologic perspective is crucial for dermatologists and healthcare professionals. Pathophysiology of Drug Hypersensitivity Syndrome The pathophysiology of DHS is multifactorial, involving immune-mediated mechanisms. The syndrome typically occurs 2 to 8 weeks after the exposure to the offending agent. Although the precise etiology remains unclear, it is believed to involve both T-cell-mediated responses and reactivation of latent viral infections, particularly human herpesvirus 6 (HHV-6) and cytomegalovirus (CMV). This suggests that genetic predispositions may also play a role, as specific HLA types have been associated with increased susceptibility to DHS. Clinical Presentation DHS often manifests with a constellation of symptoms that can mimic other dermatologic conditions. Key dermatological features include: Fever: Often presenting as an initial symptom. Rash: A morbilliform or exfoliative dermatitis that can progress to severe exfoliative erythroderma. Facial Edema: Swelling of the face can occur. Eosinophilia: An increase in eosinophils in the peripheral blood, which is a hallmark of the syndrome. Lymphadenopathy: Enlarged lymph nodes may be present in the context of systemic involvement. Organ involvement: Symptoms may extend to the liver, kidneys, lungs, and heart, leading to systemic dysfunction. Recognizing DHS is crucial because early intervention can significantly improve outcomes. Distinguishing DHS from other severe cutaneous adverse reactions (SCAR) is essential, as management strategies differ. Diagnosis The diagnosis of DHS is primarily clinical, guided by the history of drug exposure and symptomatology. The RegiSCAR scoring system aids in